Acurx Pharmaceuticals, Inc. short interest in 2023
In 2023, Acurx Pharmaceuticals, Inc.'s disclosed short interest ran from 0.20% of shares outstanding on 13 Jan 2023 to 2.17% on 29 Dec 2023, a change of +1.97 percentage points. The year's high was 4.71% on 15 Nov 2023 and its low 0.05% on 15 Aug 2023, averaging 0.82% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.22 days on 30 Nov 2023. Full history: Acurx Pharmaceuticals, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.20% (13 Jan 2023)
- End of year
- 2.17% (29 Dec 2023)
- Change
- +1.97 pp
- High
- 4.71% (15 Nov 2023)
- Low
- 0.05% (15 Aug 2023)
- Average
- 0.82%
- Highest days to cover
- 5.22 (30 Nov 2023)
- SEC filings marked
- 7
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.20% | 1.00 | |
| 31 Jan 2023 | 0.18% | 1.00 | |
| 15 Feb 2023 | 0.32% | 1.24 | |
| 28 Feb 2023 | 0.22% | 1.00 | |
| 15 Mar 2023 | 0.54% | 1.69 | 10-K filed |
| 31 Mar 2023 | 0.25% | 1.41 | results (8-K) |
| 14 Apr 2023 | 0.19% | 1.00 | |
| 28 Apr 2023 | 0.20% | 1.00 | |
| 15 May 2023 | 0.18% | 1.00 | 10-Q filed |
| 15 Jun 2023 | 0.10% | 1.00 | |
| 30 Jun 2023 | 0.07% | 1.00 | |
| 14 Jul 2023 | 0.11% | 1.00 | |
| 31 Jul 2023 | 0.16% | 1.00 | |
| 15 Aug 2023 | 0.05% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 0.11% | 1.00 | |
| 15 Sep 2023 | 0.05% | 1.00 | |
| 29 Sep 2023 | 0.08% | 1.00 | |
| 15 Nov 2023 | 4.71% | 1.34 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 4.04% | 5.22 | |
| 15 Dec 2023 | 3.19% | 1.00 | |
| 29 Dec 2023 | 2.17% | 3.02 |
See also: Acurx Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.